Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539808 | 0.76 | OPRD1 (0.53) | AGTR2 | |
| SCHEMBL20535219 | 0.76 | KDM4E (0.50) | ALDH1A1 | |
| SCHEMBL20535908 | 0.74 | LMNA (0.41) | AGTR2DAGLA | |
| SCHEMBL6342999 | 0.74 | KMT2A (0.40) | ALDH1A1 | |
| SCHEMBL7204176 | 0.73 | ALDH1A1 (0.44) | ALDH1A1AGTR2 | |
| SCHEMBL6341433 | 0.73 | ALDH1A1 (0.44) | ALDH1A1AGTR2 | |
| SCHEMBL28472037 | 0.73 | KDM4E (0.49) | ALDH1A1HCRTR1HCRTR2DAGLA | |
| SCHEMBL6540557 | 0.70 | AGTR2 (0.41) | AGTR2 | |
| SCHEMBL6540824 | 0.69 | AGTR2 (0.43) | ALDH1A1AGTR2 | |
| SCHEMBL6541032 | 0.67 | AGTR2 (0.36) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1294700-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000631-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | ALDH1A1 2029/4885TDP1 3965/4885AGER 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.